Nissan Motor Company Limited

Daiichi Sankyo Company, Limited

Ebara Corporation

Nippon Kayaku Kabushiki Kaisha

The Pokemon Company

Kabushiki Gaisha Waizen

Masao Yoshida

Hideki Miyazaki

Takeshi Masuda

Hiroyuki Naito

Yuji Kasuya

Takashi Nakada

Yuki Abe

Shinji Ashida

Yusuke Ogitani

Manabu Watanabe

Koji Morita

Osamu Tanaka

Masaya Yamamoto

Koji Matsumoto

Masahiro Inoue

Masahiko Sekimoto

Ichiro Hayakawa

Rinzo Nishizawa

Yukio Takei

Takeshi Honda

Shinya Momokawa

Fuminori Satou

Narihiro Toda

Yusuke Hirata

Kei Ono

Maki Shimada

Rieko Takano

Ryutaro Nakashima

Yoshimi Ohta

Shunta Nabetani

Akira Kyozuka

Wakana Kishi

Yasuhiko Teramoto

A customer is provided with a superior shopping experience while realizing hygiene management by using a transparent display medium with a point-of-sale (POS) terminal. Processing circuitry is configured to receive input relating to payment for a product from a first party, and display an image of an effect corresponding to the input relating to payment on the transparent display medium disposed so as to separate the first party from a second party who is purchasing the product.

Program, method, information processing device, and system for a transparent display medium

A liquid crystal optical element includes an optical function layer and two transparent substrates. The optical function layer is sandwiched between two transparent substrates. The optical function layer contains liquid crystal molecules and a photoisomerization material. The liquid crystal optical element switches between a light-transmitting state and a light-scattering state according to an orientation state of the liquid crystal molecules. The optical function layer holds the liquid crystal molecules and the photoisomerization material within a mesh structure formed of a resin-particle aggregate. Therefore, light can be strongly scattered when the liquid crystal optical element is in a screen state, and a high-contrast image is obtained when visible light is projected onto the liquid crystal optical element.

Liquid crystal optical element

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH—(CH)n-L-L-L- wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

Antibody-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the carbonyl group of the &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety with the nitrogen atom of the amino group at position 1 as the connecting position

Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-L-L- wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the carbonyl group of the &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety with the nitrogen atom of the amino group at position 1 as the connecting position. 

Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L-L-L-NH&#x2014;(CH)n-L-L-Lor -L-L-L- wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the terminal Lor Lwith the nitrogen atom of the amino group at position 1 as the connecting position. 

(Anti-HER2 antibody)-drug conjugate

Headlight for an automobile

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-L-L- or -L-L-L- wherein the antibody is connected to the terminal of L, the antitumor compound is connected to the terminal of Lor L, and any one or two or more of linkers of L, L, and Lhas a hydrophilic structure.

Antibody-drug conjugate produced by binding through linker having hydrophilic structure

A negative electrode active material for an electric device includes an alloy containing greater than or equal to 29% by mass of silicon and containing tin, carbon and inevitable impurities as a residue.

Negative electrode active material for electric device, negative electrode for electric device and electric device

A negative electrode active material for an electric device includes an alloy containing Si in a range of greater than or equal to 27% by mass and less than 100% by mass, Sn in a range of greater than 0% by mass and less than or equal to 73% by mass, V in a range of greater than 0% by mass and less than or equal to 73% by mass, and inevitable impurities as a residue. The negative electrode active material can be obtained with, for example, a multi DC magnetron sputtering apparatus by use of Si, Sn, and V as targets. An electric device using the negative electrode active material can achieve long cycle life and ensure a high capacity and cycle durability.

Negative electrode active material for electric device

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula:-L-L-L-NH&#x2014;(CH)-L-L-L-wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

Anti-HER2 antibody-drug conjugate

Growing community of inventors

Tokyo, Japan

Masao Yoshida